Brooke L. O’Donnell,Dan Stefan,Yu-Hsin Chiu,Michael J. Zeitz,Justin Tang,Danielle Johnston,Stephanie E. Leighton,Carlijn Van Kessel,Kevin Barr,Laszlo Gyenis,Taylor J. Freeman,John J. Kelly,Samar Sayedyahossein,David W. Litchfield,Kathryn Roth,James W. Smyth,Matthew Hebb,John Ronald,Douglas A. Bayliss,Silvia Penuela

Abstract:Pannexin 1 (PANX1) is upregulated in many cancers, where its activity and signalling promote tumorigenic properties. Here, we report a novel ∼25 kDa isoform of human PANX1 (hPANX1-25K) which lacks the N-terminus and was detected in several human cancer cell lines including melanoma, osteosarcoma, breast cancer and glioblastoma multiforme. This isoform was increased upon CRISPR/Cas9 deletion targeting the first exon near M1, suggesting a potential alternative translation initiation (ATI) site. hPANX1-25K was confirmed to be a hPANX1 isoform via mass spectrometry, can be N-linked glycosylated at N254, and can interact with both β-catenin and full length hPANX1. A double deletion of hPANX1 and hPANX1-25K reduces cell growth and viability in cancer cells. hPANX1-25K is prevalent throughout melanoma progression, and its levels are increased in squamous cell carcinoma cells and patient-derived tumours, compared to keratinocytes and normal skin, indicating that it may be differentially regulated in normal and cancer cells.

Novel Pannexin 1 isoform is increased in cancer